Hims Hers Health Inc (HIMS)vsHaleon plc (HLN)
HIMS
Hims Hers Health Inc
$27.51
+0.26%
HEALTHCARE · Cap: $6.57B
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 333% more annual revenue ($11.15B vs $2.58B). HLN leads profitability with a 14.5% profit margin vs -5.5%. HLN appears more attractively valued with a PEG of 2.48. HLN earns a higher WallStSmart Score of 51/100 (C-).
HIMS
Hold37
out of 100
Grade: F
HLN
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.7%
Fair Value
$27.16
Current Price
$27.51
$0.35 premium
Intrinsic value data unavailable for HLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 38.2% year-over-year
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Areas to Watch
Trading at 19.8x book value
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Revenue Growth. Revenue growth of 38.2% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Piotroski F-Score. Debt-to-equity of 4.77 is elevated, increasing financial risk.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
HIMS profiles as a hypergrowth stock while HLN is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.41 — expect wider price swings.
HIMS is growing revenue faster at 38.2% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
HLN scores higher overall (51/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?